Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 181


Molecular screening to select therapy for advanced cancer?

Tannock IF, Hickman JA.

Ann Oncol. 2019 May 1;30(5):661-663. doi: 10.1093/annonc/mdz088. No abstract available.


S55746 is a novel orally active BCL-2 selective and potent inhibitor that impairs hematological tumor growth.

Casara P, Davidson J, Claperon A, Le Toumelin-Braizat G, Vogler M, Bruno A, Chanrion M, Lysiak-Auvity G, Le Diguarher T, Starck JB, Chen I, Whitehead N, Graham C, Matassova N, Dokurno P, Pedder C, Wang Y, Qiu S, Girard AM, Schneider E, Gravé F, Studeny A, Guasconi G, Rocchetti F, Maïga S, Henlin JM, Colland F, Kraus-Berthier L, Le Gouill S, Dyer MJS, Hubbard R, Wood M, Amiot M, Cohen GM, Hickman JA, Morris E, Murray J, Geneste O.

Oncotarget. 2018 Apr 13;9(28):20075-20088. doi: 10.18632/oncotarget.24744. eCollection 2018 Apr 13.


Limits to Precision Cancer Medicine.

Tannock IF, Hickman JA.

N Engl J Med. 2017 Jan 5;376(1):96-7. doi: 10.1056/NEJMc1613563. No abstract available.


The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models.

Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O.

Nature. 2016 Oct 27;538(7626):477-482. doi: 10.1038/nature19830. Epub 2016 Oct 19.


Limits to Personalized Cancer Medicine.

Tannock IF, Hickman JA.

N Engl J Med. 2016 Sep 29;375(13):1289-94. doi: 10.1056/NEJMsb1607705. No abstract available.


Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices.

Davies EJ, Dong M, Gutekunst M, Närhi K, van Zoggel HJ, Blom S, Nagaraj A, Metsalu T, Oswald E, Erkens-Schulze S, Delgado San Martin JA, Turkki R, Wedge SR, af Hällström TM, Schueler J, van Weerden WM, Verschuren EW, Barry ST, van der Kuip H, Hickman JA.

Sci Rep. 2015 Dec 9;5:17187. doi: 10.1038/srep17187.


Three-dimensional models of cancer for pharmacology and cancer cell biology: capturing tumor complexity in vitro/ex vivo.

Hickman JA, Graeser R, de Hoogt R, Vidic S, Brito C, Gutekunst M, van der Kuip H; IMI PREDECT Consortium.

Biotechnol J. 2014 Sep;9(9):1115-28. doi: 10.1002/biot.201300492. Review.


S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab.

Burbridge MF, Bossard CJ, Saunier C, Fejes I, Bruno A, Léonce S, Ferry G, Da Violante G, Bouzom F, Cattan V, Jacquet-Bescond A, Comoglio PM, Lockhart BP, Boutin JA, Cordi A, Ortuno JC, Pierré A, Hickman JA, Cruzalegui FH, Depil S.

Mol Cancer Ther. 2013 Sep;12(9):1749-62. doi: 10.1158/1535-7163.MCT-13-0075. Epub 2013 Jun 26.


N-terminally cleaved Bcl-xL mediates ischemia-induced neuronal death.

Ofengeim D, Chen YB, Miyawaki T, Li H, Sacchetti S, Flannery RJ, Alavian KN, Pontarelli F, Roelofs BA, Hickman JA, Hardwick JM, Zukin RS, Jonas EA.

Nat Neurosci. 2012 Feb 26;15(4):574-80. doi: 10.1038/nn.3054.


Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xL.

Gautier F, Guillemin Y, Cartron PF, Gallenne T, Cauquil N, Le Diguarher T, Casara P, Vallette FM, Manon S, Hickman JA, Geneste O, Juin P.

Mol Cell Biol. 2011 Feb;31(4):832-44. doi: 10.1128/MCB.00161-10. Epub 2010 Dec 20.


Only a subset of Met-activated pathways are required to sustain oncogene addiction.

Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L.

Sci Signal. 2009;2(102):er11.


Only a subset of Met-activated pathways are required to sustain oncogene addiction.

Bertotti A, Burbridge MF, Gastaldi S, Galimi F, Torti D, Medico E, Giordano S, Corso S, Rolland-Valognes G, Lockhart BP, Hickman JA, Comoglio PM, Trusolino L.

Sci Signal. 2009 Dec 8;2(100):ra80. doi: 10.1126/scisignal.2000643. Erratum in: Sci Signal. 2009 Dec 22;2(102):er11. Corrected and republished in: Sci Signal. 2009;2(102):er11.


An unusual DNA binding compound, S23906, induces mitotic catastrophe in cultured human cells.

Cahuzac N, Studény A, Marshall K, Versteege I, Wetenhall K, Pfeiffer B, Léonce S, Hickman JA, Pierré A, Golsteyn RM.

Cancer Lett. 2010 Mar 28;289(2):178-87. doi: 10.1016/j.canlet.2009.08.014. Epub 2009 Sep 15.


Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members.

Gallenne T, Gautier F, Oliver L, Hervouet E, Noël B, Hickman JA, Geneste O, Cartron PF, Vallette FM, Manon S, Juin P.

J Cell Biol. 2009 Apr 20;185(2):279-90. doi: 10.1083/jcb.200809153.


Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.

Marty B, Maire V, Gravier E, Rigaill G, Vincent-Salomon A, Kappler M, Lebigot I, Djelti F, Tourdès A, Gestraud P, Hupé P, Barillot E, Cruzalegui F, Tucker GC, Stern MH, Thiery JP, Hickman JA, Dubois T.

Breast Cancer Res. 2008;10(6):R101. doi: 10.1186/bcr2204. Epub 2008 Dec 3.


Bcl-xL induces Drp1-dependent synapse formation in cultured hippocampal neurons.

Li H, Chen Y, Jones AF, Sanger RH, Collis LP, Flannery R, McNay EC, Yu T, Schwarzenbacher R, Bossy B, Bossy-Wetzel E, Bennett MV, Pypaert M, Hickman JA, Smith PJ, Hardwick JM, Jonas EA.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):2169-74. doi: 10.1073/pnas.0711647105. Epub 2008 Feb 4.


Bcl-xL inhibitor ABT-737 reveals a dual role for Bcl-xL in synaptic transmission.

Hickman JA, Hardwick JM, Kaczmarek LK, Jonas EA.

J Neurophysiol. 2008 Mar;99(3):1515-22. Epub 2007 Dec 26.


Cell cycle-dependent induction of autophagy, mitophagy and reticulophagy.

Tasdemir E, Maiuri MC, Tajeddine N, Vitale I, Criollo A, Vicencio JM, Hickman JA, Geneste O, Kroemer G.

Cell Cycle. 2007 Sep 15;6(18):2263-7. Epub 2007 Jul 2.


Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.

Lansiaux A, Léonce S, Kraus-Berthier L, Bal-Mahieu C, Mazinghien R, Didier S, David-Cordonnier MH, Hautefaye P, Lavielle G, Bailly C, Hickman JA, Pierré A.

Mol Pharmacol. 2007 Aug;72(2):311-9. Epub 2007 May 9.


Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1.

Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, Hickman JA, Geneste O, Kroemer G.

EMBO J. 2007 May 16;26(10):2527-39. Epub 2007 Apr 19.


BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L).

Maiuri MC, Criollo A, Tasdemir E, Vicencio JM, Tajeddine N, Hickman JA, Geneste O, Kroemer G.

Autophagy. 2007 Jul-Aug;3(4):374-6. Epub 2007 Jul 4.


Positive regulation of apoptosis by HCA66, a new Apaf-1 interacting protein, and its putative role in the physiopathology of NF1 microdeletion syndrome patients.

Piddubnyak V, Rigou P, Michel L, Rain JC, Geneste O, Wolkenstein P, Vidaud D, Hickman JA, Mauviel A, Poyet JL.

Cell Death Differ. 2007 Jun;14(6):1222-33. Epub 2007 Mar 23.


Blockade of alpha v beta3 and alpha v beta5 integrins by RGD mimetics induces anoikis and not integrin-mediated death in human endothelial cells.

Maubant S, Saint-Dizier D, Boutillon M, Perron-Sierra F, Casara PJ, Hickman JA, Tucker GC, Van Obberghen-Schilling E.

Blood. 2006 Nov 1;108(9):3035-44. Epub 2006 Jul 11.


Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment.

Borgne A, Versteege I, Mahé M, Studeny A, Léonce S, Naime I, Rodriguez M, Hickman JA, Meijer L, Golsteyn RM.

Oncogene. 2006 Nov 30;25(56):7361-72. Epub 2006 Jun 19.


Cell cycle specific induction of HL-60 cell differentiation and apoptosis by mycophenolic acid.

Görtz A, Franklin TJ, Dive C, Hickman JA.

Cell Death Differ. 1997 Dec;4(8):787-95.


Covalent binding of antitumor benzoacronycines to double-stranded DNA induces helix opening and the formation of single-stranded DNA: unique consequences of a novel DNA-bonding mechanism.

David-Cordonnier MH, Laine W, Lansiaux A, Rosu F, Colson P, de Pauw E, Michel S, Tillequin F, Koch M, Hickman JA, Pierré A, Bailly C.

Mol Cancer Ther. 2005 Jan;4(1):71-80.


Exposure to hypoxia rapidly induces mitochondrial channel activity within a living synapse.

Jonas EA, Hickman JA, Hardwick JM, Kaczmarek LK.

J Biol Chem. 2005 Feb 11;280(6):4491-7. Epub 2004 Nov 23.


Proapoptotic N-truncated BCL-xL protein activates endogenous mitochondrial channels in living synaptic terminals.

Jonas EA, Hickman JA, Chachar M, Polster BM, Brandt TA, Fannjiang Y, Ivanovska I, Basañez G, Kinnally KW, Zimmerberg J, Hardwick JM, Kaczmarek LK.

Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13590-5. Epub 2004 Sep 1.


Shooting at survivors: Bcl-2 family members as drug targets for cancer.

Juin P, Geneste O, Raimbaud E, Hickman JA.

Biochim Biophys Acta. 2004 Mar 1;1644(2-3):251-60. Review. No abstract available.


Synthesis of N,N'-disubstituted 3-aminobenzo[c] and [d]azepin-2-ones as potent and specific farnesyl transferase inhibitors.

Le Diguarher T, Ortuno JC, Shanks D, Guilbaud N, Pierré A, Raimbaud E, Fauchère JL, Hickman JA, Tucker GC, Casara PJ.

Bioorg Med Chem Lett. 2004 Feb 9;14(3):767-71.


Modulation of synaptic transmission by the BCL-2 family protein BCL-xL.

Jonas EA, Hoit D, Hickman JA, Brandt TA, Polster BM, Fannjiang Y, McCarthy E, Montanez MK, Hardwick JM, Kaczmarek LK.

J Neurosci. 2003 Sep 10;23(23):8423-31.


Structure-activity relationships and mechanism of action of antitumor benzo[b]pyrano[3,2-h]acridin-7-one acronycine analogues.

Thi Mai HD, Gaslonde T, Michel S, Tillequin F, Koch M, Bongui JB, Elomri A, Seguin E, Pfeiffer B, Renard P, David-Cordonnier MH, Laine W, Bailly C, Kraus-Berthier L, Léonce S, Hickman JA, Pierré A.

J Med Chem. 2003 Jul 3;46(14):3072-82.


Parallel liquid synthesis of N,N'-Disubstituted 3-amino azepin-2-ones as potent and specific farnesyl transferase inhibitors.

Le Diguarher T, Ortuno JC, Dorey G, Shanks D, Guilbaud N, Pierré A, Fauchère JL, Hickman JA, Tucker GC, Casara PJ.

Bioorg Med Chem. 2003 Jul 17;11(14):3193-204.


Decrease in survival threshold of quiescent colon carcinoma cells in the presence of a small molecule integrin antagonist.

Burbridge MF, Venot V, Casara PJ, Perron-Sierra F, Hickman JA, Tucker GC.

Mol Pharmacol. 2003 Jun;63(6):1281-8.


Post-translational modification of Bid has differential effects on its susceptibility to cleavage by caspase 8 or caspase 3.

Degli Esposti M, Ferry G, Masdehors P, Boutin JA, Hickman JA, Dive C.

J Biol Chem. 2003 May 2;278(18):15749-57. Epub 2003 Feb 21.


Alkylation of guanine in DNA by S23906-1, a novel potent antitumor compound derived from the plant alkaloid acronycine.

David-Cordonnier MH, Laine W, Lansiaux A, Kouach M, Briand G, Pierré A, Hickman JA, Bailly C.

Biochemistry. 2002 Aug 6;41(31):9911-20.


Changes and challenges--the world post-Gleevec (Glivec).

Hickman JA, Lazo JS.

Curr Opin Pharmacol. 2002 Aug;2(4):357-60. No abstract available.


Acronycine derivatives as promising antitumor agents.

Guilbaud N, Léonce S, Tillequin F, Koch M, Hickman JA, Pierré A.

Anticancer Drugs. 2002 Jun;13(5):445-9. Review.


Induction of apoptosis in HL-60 leukemia and B16 melanoma cells by the acronycine derivative S23906-1.

Kluza J, Lansiaux A, Wattez N, Hildebrand MP, Léonce S, Pierré A, Hickman JA, Bailly C.

Biochem Pharmacol. 2002 Apr 15;63(8):1443-52.


Apoptosis and tumourigenesis.

Hickman JA.

Curr Opin Genet Dev. 2002 Feb;12(1):67-72. Review.


Cellular damage signals promote sequential changes at the N-terminus and BH-1 domain of the pro-apoptotic protein Bak.

Griffiths GJ, Corfe BM, Savory P, Leech S, Esposti MD, Hickman JA, Dive C.

Oncogene. 2001 Nov 15;20(52):7668-76.


Induction of cyclin E and inhibition of DNA synthesis by the novel acronycine derivative S23906-1 precede the irreversible arrest of tumor cells in S phase leading to apoptosis.

Léonce S, Pérez V, Lambel S, Peyroulan D, Tillequin F, Michel S, Koch M, Pfeiffer B, Atassi G, Hickman JA, Pierré A.

Mol Pharmacol. 2001 Dec;60(6):1383-91.


Damage-induced Bax N-terminal change, translocation to mitochondria and formation of Bax dimers/complexes occur regardless of cell fate.

Makin GW, Corfe BM, Griffiths GJ, Thistlethwaite A, Hickman JA, Dive C.

EMBO J. 2001 Nov 15;20(22):6306-15.


Bid, a widely expressed proapoptotic protein of the Bcl-2 family, displays lipid transfer activity.

Esposti MD, Erler JT, Hickman JA, Dive C.

Mol Cell Biol. 2001 Nov;21(21):7268-76.


Disruption of focal adhesions mediates detachment during neuronal apoptosis.

Lesay A, Hickman JA, Gibson RM.

Neuroreport. 2001 Jul 20;12(10):2111-5.


MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells.

Rodriguez-Lopez AM, Xenaki D, Eden TO, Hickman JA, Chresta CM.

Mol Pharmacol. 2001 Jan;59(1):135-43.


Bcl-w is an important determinant of damage-induced apoptosis in epithelia of small and large intestine.

Pritchard DM, Print C, O'Reilly L, Adams JM, Potten CS, Hickman JA.

Oncogene. 2000 Aug 10;19(34):3955-9.


Apoptosis and cancer chemotherapy.

Makin G, Hickman JA.

Cell Tissue Res. 2000 Jul;301(1):143-52. Review.


Supplemental Content

Loading ...
Support Center